NICE has developed a medtech innovation briefing (MIB) on the AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis.
AdenoPlus is a point-of-care test for diagnosing acute adenoviral conjunctivitis in people of all ages, and can be used in any healthcare setting. Two prospective diagnostic accuracy studies showed the sensitivity of AdenoPlus to be 85% and 39.5%, and its specificity to be 98% and 95.5%, compared with existing laboratory tests. A box of 10 single-use AdenoPlus tests costs £150, excluding VAT. The test needs no additional equipment or consumables.
Medtech innovation briefings provide a description of the medical technology, including its likely place in therapy, the costs of using the technology and a critical review of the strengths and weaknesses of the relevant published evidence.
Their purpose is to provide objective information on device and diagnostic technologies to aid local decision-making by clinicians, managers and procurement professionals. By making this information available, NICE helps to avoid the need for NHS organisations to produce similar information for local use.
Medtech innovation briefings are not NICE guidance. They differ in format, contain no judgement on the value of the technology and do not constitute a guidance recommendation.
MIBs are commissioned by NHS England and produced in support of the NHS 5 Year Forward View, specifically as one of a number of steps which will accelerate innovation in new treatments and diagnostics.